← Back to Search

Device

Static Magnetic and Electric (sBE) device for Glioblastoma

N/A
Waitlist Available
Research Sponsored by Varun Monga, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during the initial 8 weeks of treatment
Awards & highlights

Study Summary

This trial will study whether it is safe and feasible to use a home-based device that applies static magnetic and electric fields for 8 hours during sleep in adults with recurrent glioblastoma at their first relapse.

Eligible Conditions
  • Glioblastoma (GBM)
  • Glioblastoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during the initial 8 weeks of treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and during the initial 8 weeks of treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse Events according to CTCAE v5.0
Greater than or equal to 80% sBE compliance as determined by device pressor sensors, participant reporting via daily diary, and participant completion of sBE Device Questionnaire

Trial Design

2Treatment groups
Experimental Treatment
Group I: Patients: sBE device applied during sleep, in combination with Lomustine and BevacizumabExperimental Treatment3 Interventions
The sBE device is to be used 8 hours a day by the patients, during sleep, for 8 weeks, while also receiving standard chemotherapy Lomustine and Bevacizumab
Group II: Partners of Patients (who sleep in same bed): sBEExperimental Treatment1 Intervention
Up to 12 associated unaffected partners may agree to sleep within the investigational sBE device congruent with the period of exposure of their rGBM partner (8 weeks + possible extension)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lomustine
FDA approved
Bevacizumab
FDA approved

Find a Location

Who is running the clinical trial?

Varun Monga, MDLead Sponsor
6 Previous Clinical Trials
136 Total Patients Enrolled
1 Trials studying Glioblastoma
10 Patients Enrolled for Glioblastoma
University of IowaOTHER
443 Previous Clinical Trials
878,690 Total Patients Enrolled
2 Trials studying Glioblastoma
203 Patients Enrolled for Glioblastoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any participants needed for this experiment at the current time?

"Unfortunately, this particular study is no longer looking for participants, as seen on clinicaltrials.gov. The study's first posting was on April 1st, 2023 and the last update was on September 20th, 2023. However, there are over 1400 other trials that are still recruiting patients."

Answered by AI
~0 spots leftby Aug 2026